Orchestra BioMed Holdings, Inc. Shares have lost about 48.4% since the beginning of the year versus the S&P 500's gain of 9.5%. What's Next for Orchestra BioMed Holdings, Inc. Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5%. A quarter ago, it was exp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number: 001-39421 ORCHESTRA BIOMED HOLDINGS, INC. (Exact name of registrant as specif ...

Patent estate covering atrioventricular interval modulation ("AVIM") therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the treatment of hypertensionAVIM therapy is currently being studied in the BACKBEAT global pivotal study in collaboration with MedtronicOrchestra BioMed to provide detailed overview of AVIM therapy and the BACKBEAT global pivotal study in upcoming R&D day on June 11, 2024 in New York City NEW HOPE, Pa., April 30, ...

NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024 at 10:00 AM ET. To register, click here. The event will feature presentations by company management and key opinion leaders related to the Company's lea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 | Delaware | 92-2038755 | | --- | --- | | (State or other jurisdiction of | (IRS Employer | | incorporation or organization) | Identification No.) | | 150 Union Square Drive | | | New Hope, Pennsylvania 18938 | | | (Address of principal executive offices, including zip co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number: 001-39421 ORCHESTRA BIOMED HOLDINGS, INC. (Exact name of registrant as sp ...

Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q Delaware 92-2038755 (State or other jurisdiction of incorporation or organization) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 (IRS Employer Identification No.) 150 Union Square Drive New Hope, Pennsylvania 18938 (Address of principal executive offices, including zip code) Registrant's t ...

Financial Performance - The net losses for the three months ended March 31, 2023, and 2022 were $10.9 million and $5.7 million, respectively, with an accumulated deficit of $210.7 million as of March 31, 2023[191]. - Total revenue for the three months ended March 31, 2023, was $1.164 million, a 34% increase from $866,000 in the same period of 2022[213]. - Partnership revenue increased by $303,000, or approximately 42%, to $1.0 million in Q1 2023 from $716,000 in Q1 2022[214]. - Net loss for the three months ended March 31, 2023, was $10.9 million, compared to a net loss of $5.7 million in the same period of 2022, representing a 91% increase in losses[227]. - Cash and cash equivalents as of March 31, 2023, were $18.7 million, with an additional $108.4 million in short-term marketable securities[227]. - Net cash used in operating activities for Q1 2023 was $14.4 million, compared to $5.3 million in Q1 2022, indicating a significant increase in cash outflow[232]. - Net cash used in investing activities for Q1 2023 was $43.5 million, primarily for marketable securities[234]. - Net cash provided by financing activities for Q1 2023 was $56.8 million, attributed to net proceeds from the Business Combination[235]. Agreements and Partnerships - The company raised a cumulative $166.8 million through the issuance of convertible preferred stock and $70.0 million from the business combination, with an additional $30.0 million received from the Terumo Agreement as of March 31, 2023[191]. - The company has recognized $11.5 million in cumulative partnership revenues from the Terumo Agreement from 2019 through March 31, 2023[199]. - Under the Terumo Agreement, the company is eligible for milestone payments totaling $65 million, with $35 million related to achieving specific milestones by target dates[198]. - The company entered into the Medtronic Agreement in June 2022 for the development and commercialization of BackBeat CNT, with no revenue recognized under this agreement as of March 31, 2023[200]. - Partnership revenues related to the Terumo Agreement may include milestone payments and royalties, with an increase in partnership revenues of $81,000 in Q1 2023[252]. - The Terumo Agreement includes development and regulatory milestone payments, evaluated for probability of achievement at each reporting period[249]. Expenses - Research and development expenses are expected to increase in absolute dollars as the company continues to develop new products and enhance existing technologies[205]. - Selling, general and administrative expenses are anticipated to rise as the company incurs additional costs associated with operating as a public entity[206]. - Research and development expenses rose by $4.8 million, or approximately 138%, to $8.3 million in Q1 2023, primarily due to increased support for ongoing projects[220]. - Selling, general and administrative expenses increased by $1.9 million, or approximately 78%, to $4.4 million in Q1 2023, driven by higher headcount and associated costs[222]. Stock-Based Compensation - Stock-based compensation is measured at fair value using the Black-Scholes option-pricing model, with expenses recognized over the vesting period[258]. - Stock-based compensation for Q1 2023 was $1.5 million, a significant increase from $70,000 in Q1 2022[265]. - As of March 31, 2023, the company had approximately $11.2 million of total unrecognized stock-based compensation, expected to be recognized over a weighted-average period of approximately 3 years[265]. - The fair value of stock options is estimated based on various factors, including market conditions and company performance[260]. - The expected term for stock-based awards is determined using the "simplified" method, which is the midpoint between the vesting date and the contractual life of the awards[264]. - The expected volatility for stock-based awards is derived from historical stock volatilities of comparable peer public companies[264]. - Stock-based compensation increased significantly, indicating a potential focus on employee incentives and retention strategies[265]. Company Classification and Market Activity - The company remains classified as an "emerging growth company" and will maintain this status until it meets certain revenue or market capitalization thresholds[269]. - The company is also classified as a "smaller reporting company," allowing it to take advantage of scaled disclosures as long as its market value remains below $250 million or annual revenue is below $100 million[270]. - The company’s common stock began trading on The Nasdaq Global Market under the symbol "OBIO" on January 27, 2023, following the business combination[188]. - The expected dividend yield is zero, with no dividends anticipated in the foreseeable future[264]. - The fair value of the company's common stock is determined based on the closing price around the date of grant following the business combination[264]. Other Financial Information - The business combination was accounted for as a reverse recapitalization, treating Legacy Orchestra as the acquirer for financial reporting purposes[189]. - Total contractual obligations as of March 31, 2023, amounted to $16.58 million, with $1.72 million due within one year[238]. - The loss on fair value adjustment of warrant liability was $294,000 for Q1 2023, compared to a loss of $145,000 in Q1 2022, reflecting changes in the fair value of outstanding warrants[225]. - Research and development costs are estimated and accrued based on discussions with service providers regarding the progress of clinical studies[255]. - The estimated total costs associated with the Terumo Agreement decreased by approximately 0.7% as of March 31, 2023, compared to estimates from December 31, 2022[215].

Corporate Presentation Q1 2023 2 This presentation has been prepared for informational purposes only from information supplied by Orchestra BioMed Holdings, Inc., referred to herein as "we," "our," "Orchestra BioMed," and "the Company," and from third-party sources indicated herein. Such third-party information has not been independently verified. Orchestra BioMed makes no representation or warranty, expressed or implied, as to the accuracy or completeness of such information. This presentation contains for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001-39421 HEALTH SCIENCES ACQUISITIONS CORPORATION 2 (Exact name of registrant as specified in its charter) | Cayman ...